Citations

Clear

16280 citation(s) found for "Yu, David".

Validation of Current Staging Systems in HNCSCC : A Multinational Cohort Study
Girardi, Fábio Muradás , Machado, Cristian David Cardona , Wysong, Ashley, Ran, Nina A., Granger, Emily , Koyfman, Shlomo A. , Vidimos, Allison T. , Carr, David R. , Shahwan, Kathryn T., Hirotsu, Kelsey E. , Carter, Joi B., Mangold, Aaron R. , Brodland, David G., Zitelli, John A. , Willenbrink, Tyler J., Jambusaria‐Pahlajani, Anokhi , Nijhawan, Rajiv I. , Ruiz, Emily S. , Cañueto, Javier , Granger, Emily E , Shahwan, Kathryn T , Willenbrink, Tyler J , Mangold, A R , Wagner, Vivian Petersen , Wysong, Ashley , Carr, David R., Carucci, John A. , Srivastava, Divya

Mayo Clinic

Head & Neck | July 25, 2025 | Volume: 47 | Issue: 12 | Pages: 3385-3393

10.1002/hed.28259 | PMID 40709408 Get It

ABSTRACT Importance Risk stratification of cutaneous squamous cell carcinoma (CSCC) is central to effective management. Despite advancements in the 8th edition of the American Joint Committee on Cancer (AJCC8) staging system, the distinctiveness of T‐stages remains limited. Objective To evaluate the effectiveness of the Brigham and Women's Hospital (BWH) and the AJCC8 staging systems in predicting poor outcomes in head and neck (HN) CSCC. Design A retrospective, multinational cohort study of CSCCs diagnosed between January 10, 1991, and December 31, 2023. Setting Twelve centers across the United States (10), Spain (1), and Brazil (1). Participants Patients with invasive CSCC who underwent curative‐intent surgical treatment. Exclusions included cases of lip CSCC, cases with prior HN cancer with associated regional disease, patients with a history of chemotherapy/radiotherapy for other HN neoplasms, and recurrent primary tumors. Exposure Tumors were staged according to both the AJCC8 TNM staging system and the BWH tumor classification. Main Outcomes and Measures Local recurrence (LR), nodal recurrence (NR), distant recurrence (DR), and disease‐specific death (DSD). Results A total of 9852 excised tumors from 3168 patients were included. The 2 systems had comparable monotonicity and homogeneity. Significant differences could be observed in 5‐year cumulative incidence for DSD in both BWH and AJCC8, and also for LR in BWH. Higher T‐stages exhibited similar curves regarding NR and DR for both AJCC8 and BWH staging systems. Overall, we observed high specificity and NPV, low sensitivity and PPV, and moderately high c‐indices for both the BWH and AJCC8 staging systems in predicting the main outcomes for HNCSCC. Conclusion and Relevance Current AJCC8 and BWH staging systems can accurately predict survival in HNCSCC, although there are still important characteristics to be addressed in future staging systems for better stratification according to the other main outcomes.
A proposed clinical guide to delivering Lower Extremity Extracorporeal Distal Revascularization (LEEDR) as a bridge to definitive care in acute limb ischemia
Dvir, May , Jodłowski, Grzegorz , Stonko, David P. , Nelson, Jack, Morrison, Jonathan J. , Treffalls, Rebecca, Morrison, Jonathan J , Stonko, David P , Treffalls, Rebecca N. , Nelson, Jack, Walker, Patrick F.

Mayo Clinic

Perfusion | July 25, 2025 | Volume: 41 | Issue: 3 | Pages: 254-259

10.1177/02676591251363374 | PMID 40708295 Get It

Introduction Lower Extremity Extracorporeal Distal Revascularization (LEEDR) is a novel, preclinically tested technique designed to provide temporary limb perfusion in cases of acute limb ischemia when immediate revascularization is not feasible. Methods LEEDR employs an extracorporeal pump and circuit to draw arterial blood from a proximal inflow site and deliver it to an outflow artery within the ischemic limb. The system is designed for bedside initiation using percutaneous access. Results ALI from embolism, thrombosis, or trauma rapidly leads to irreversible tissue damage. Delays in revascularization are associated with high rates of limb loss and systemic complications. LEEDR offers a time-sensitive intervention aimed at mitigating these risks and preserving limb viability until definitive treatment is available. Conclusion LEEDR is a promising temporary perfusion strategy for limb salvage in ALI. This manuscript outlines its procedural components, technical considerations, and anticipated role in bridging patients to definitive revascularization.
Comparative Effectiveness Research Using Randomized Trials and Observational Studies: Validity and Feasibility Considerations
Bikdeli, Behnood , Bukhari, Syed , You, Seng Chan , Wallach, Joshua D. , Lip, Gregory Y H , Wallach, Joshua D , Ross, Joseph S. , Jeffery, Molly Moore , Cohen, David Jonathan , Januzzi, James Louis

Mayo Clinic

Thrombosis and Haemostasis | July 24, 2025 | Volume: 126 | Issue: 04 | Pages: 335-345

10.1055/a-2664-7887 | PMID 40719151 Get It

Abstract In comparative effectiveness research (CER), ensuring internal, construct, and external validity is crucial. Internal validity determines whether observed outcomes are causally linked to an intervention; construct validity assesses whether a study measures what it intends to; and external validity relates to generalizability in routine practice. Double-blind randomized trials optimize internal validity by minimizing bias and confounding, while construct validity is strengthened through pre-specified protocols and standardized data collection. However, controlled conditions limit external validity. Pragmatic RCTs improve generalizability but may compromise internal validity due to open-label designs. Observational CER studies—including observational studies following the target trial emulation framework—offer broader external validity and feasibility in less time and at lower cost. However, due to lack of random assignment, these studies are susceptible to measured and unmeasured confounding. Several techniques help mitigate these concerns, including a detailed pre-specified protocol, tools such as propensity score matching to balance measured confounders, falsification endpoint testing for assessing the presence of unmeasured confounders, and quasi-experimental designs (including instrumental variable analysis), which may be able to address both. Pre-specified sensitivity analyses and triangulation with complementary data sources further enhance robustness. Construct validity in observational CER depends on accurate patient profiling and validated computational phenotypes for identifying patients, exposures, and outcomes. Thoughtful study design and analytic rigor are essential for balancing these validity considerations. This brief review highlights these issues with examples from thrombosis research.
Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis
Ahmed, Nausheen , Kambhampati, Swetha , Hamadani, Mehdi , Hu, Zhen‐Huan , Grover, Natalie S. , Shadman, Mazyar , Locke, Frederick L. , Gerson, James N. , Frank, Matthew J. , Budde, Lihua E. , Wang, Michael , Bye, Matthew , Kharfan‐Dabaja, Mohamed A. , Sauter, Craig S. , Logan, Brent R., Nunes, Ana, Dalton, David , Kloos, Ioana , Xu, Hairong, Pasquini, Marcelo C. , Herrera, Alex F. , Thiruvengadam, Swetha Kambhampati , Grover, Natalie S , Gerson, James , Kim, Soyoung , Kharfan-Dabaja, Mohamed A , Hematti, Peiman , Turtle, Cameron J , Ahmed, Sairah , Moskop, Amy , Nunes, Ana , Dalton, David , Pasquini, Marcelo , Herrera, Alex F , Hamadani, Mehdi , Shadman, Mazyar , Ahmed, Nausheen , Locke, Frederick L , Kim, Soyoung , Hematti, Peiman , Turtle, Cameron J. , Ahmed, Sairah , Moskop, Amy , Lee, Daniel Y.

Mayo Clinic

Blood Advances | July 24, 2025 | Volume: 9 | Issue: 20 | Pages: 5382-5396

10.1182/bloodadvances.2024015014 | PMID 40706035 Get It

Abstract Brexucabtagene autoleucel (brexu-cel) is a chimeric antigen receptor T-cell therapy approved for relapsed/refractory mantle cell lymphoma (R/R MCL). Here, we report real-world effectiveness and safety outcomes of brexu-cel in a prospective study of patients with R/R MCL, including subgroups based on prior treatment with Bruton's tyrosine kinase inhibitor, bendamustine, or autologous hematopoietic cell transplant (auto-HCT) and number of prior therapy lines, using Center for International Blood and Marrow Transplant Research registry data. A total of 476 patients with R/R MCL who received brexu-cel between July 2020 and December 2022 were included in the analysis. With a median follow-up of 13.5 months, the overall response rate was 91% and complete response rate was 82%. One-year overall survival and progression-free survival rates were 76% and 63%, respectively. One-year cumulative incidence of nonrelapse mortality was 8%. Prior auto-HCT was associated with better duration of response within 6 months after infusion (hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.28-0.85) but greater risk of immune effector cell–associated neurotoxicity syndrome (odds ratio [OR], 1.66; 95% CI, 1.06-2.60). Prior bendamustine was associated with increased risk of prolonged thrombocytopenia (OR, 1.90; 95% CI, 1.13-3.21). In patients with 1 to 2 prior therapy lines, relapse or progression was less frequent compared with those with ≥3 prior lines (HR, 0.64; 95% CI, 0.42-1.00). Collectively, our results suggest that real-world outcomes with brexu-cel were consistent with those of the ZUMA-2 trial, regardless of prior therapy type or number of prior therapy lines.
Mitochondrial dysfunction drives basal cell hyperplasia in eosinophilic oesophagitis
Morimoto, Masaki , Kawasaki, Kento , McNamee, Niamh , Shimonosono, Rieko, Shimonosono, Masataka , Matsuura, Norihiro, Tomita, Yasuto, Hirose, Wataru , Teranishi, Ryugo , Itami, Takefumi, Guha, Manti , Rajagopalan, Pavithra, Martin, Cecilia , Golden, Hailey, Dhakal, Diya, Wilkins, Benjamin J. , Wangensteen, Kirk J. , Pomenti, Sydney , Katzka, David A. , Que, Jianwen , Whelan, Kelly A. , Muir, Amanda B. , Kita, Hirohito , Wright, Benjamin L. , Doyle, Alfred D. , Teranishi, Ryugo , Abrams, Julian A , Katzka, D A , Wright, Benjamin L , Sachdeva, Uma M , Kita, H , Wangensteen, Kirk J , Que, Jianwen , Flashner, Samuel , Matsuura, Norihiro , Hirose, Wataru, Itami, Takefumi, Golden, Hailey, Klein–Szanto, Andres J. , Nakagawa, Hiroshi

Mayo Clinic

Gut | July 23, 2025 | Volume: 74 | Issue: 10 | Pages: 1571-1588

10.1136/gutjnl-2024-334561 | PMID 40701793 Get It

Background Eosinophilic oesophagitis (EoE) is a food allergen-induced inflammatory disorder characterised by interleukin (IL)-13-mediated oesophageal inflammation and epithelial basal cell hyperplasia (BCH). The role of mitochondria in EoE pathogenesis remains elusive. Design Prompted by single cell transcriptomics data, we interrogated the role of mitochondria in EoE pathobiology using patient biopsies, EoE-mouse models and oesophageal epithelial cells grown in monolayer and three-dimensional (3D) organoid cultures treated with EoE-relevant cytokines. 3D organoids and EoE-bearing mice were treated with omeprazole—a proton-pump inhibitor used as first-line EoE therapy. We performed CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) interference in mouse organoids to identify the key mitochondrial regulatory genes whose depletion may lead to BCH. We analysed mitochondrial membrane potential, mass and superoxide production by flow cytometry, cellular oxygen consumption by respirometry, mitochondrial structures and perturbation of cellular energy homeostasis by immunoblotting. Results Mitochondrial dysfunction appeared to be a hallmark of EoE-related BCH where mitochondrial structural damage was associated with impaired oxidative respiratory capacity, elevation of mitochondrial superoxide and decreased adenosine triphosphate (ATP) production, as corroborated by activation of the adenosine monophosphate (AMP) -activated protein kinase and suppression of mammalian target-of-rapamycin signalling. Depletion of PGC1A, the master regulator of mitochondria biogenesis, recapitulated EoE-related BCH, suggesting that mitochondrial dysfunction drives BCH. Further, omeprazole alleviated mitochondrial damage and dysfunction in EoE-related BCH modelled in mice and patient-derived organoids. Conclusion Mitochondrial dysfunction is tightly linked to perturbation of redox homeostasis in EoE-related BCH, which is promoted by IL-13 and reversible with omeprazole treatment.
Robotic Surgery in Emergency Colorectal Procedures: Analysis of Outcomes and Future Trends
Violante, Tommaso , Novelli, Marco , Sileo, Annaclara , Violante, Tommaso , Ferrari, Davide, Sassun, Richard , Larson, David W.

Mayo Clinic

Journal of the American College of Surgeons | July 23, 2025 | Volume: 241 | Issue: 6 | Pages: 1013-1025

10.1097/xcs.0000000000001500 | PMID 40698773 Get It

BACKGROUND: Emergency colorectal surgery traditionally uses open approaches, with limited minimally invasive adoption. Although robotic surgery demonstrates benefits in elective procedures, its role in emergency settings remains unclear. This retrospective study evaluated outcomes of robotic vs laparoscopic and open approaches in emergency colorectal procedures and predicted future adoption trends. STUDY DESIGN: We analyzed 83,483 patients from the American College of Surgeons NSQIP database (2012 to 2021) who underwent emergency colorectal surgery: 53,731 open, 26,649 laparoscopic, and 3,103 robotic procedures. Outcomes were analyzed using multivariable regression, propensity score matching, and g-computation analysis. Classification and Regression Trees were used to analyze surgical approaches to selection factors, whereas vector autoregressive models projected future usage trends. RESULTS: Robotic surgery demonstrated significantly lower conversion rates to open surgery compared with laparoscopy (7.8% vs 24.2%; adjusted odds ratio 0.32, 95% CI 0.28 to 0.36), shorter length of stay (incidence rate ratio 0.67, 95% CI 0.65 to 0.69), and fewer surgical complications (odds ratio 0.65, 95% CI 0.60 to 0.72). Robotic usage increased from 0% to 6.6% (2012 to 2021), with trends suggesting substantial growth toward 20.2% by 2025. Patient selection favored robotics for stable patients with diverticulitis (68.4%) and cancer without sepsis, whereas open surgery remained predominant in patients with perforation, severe sepsis, or significant comorbidities. CONCLUSIONS: In selected emergency colorectal procedures, robotic surgery demonstrates superior outcomes vs conventional approaches. These outcomes may be partially influenced by patient selection factors because robotic cases involved more clinically stable patients. These findings support expanded robotic platform availability for emergency procedures, although careful patient selection remains essential. The projected increase in robotic usage reflects a growing acceptance of this technology, suggesting that its technical advantages can extend to more complex emergency cases than previously considered.
Super Learner Enhances Postoperative Complication Prediction in Colorectal Surgery
Violante, Tommaso , Novelli, Marco , Perry, William , Mathis, Kellie L. , Dozois, Eric J. , Violante, Tommaso , Perry, William R , Ferrari, Davide , Larson, David W.

Mayo Clinic

Annals of Surgery | July 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/sla.0000000000006847 | PMID 40698768 Get It

Objective: To determine if a Super Learner (SL) machine learning approach could improve the predictive accuracy of the American College of Surgeons Risk Calculator (ACS-RC) for postoperative complications in patients undergoing colorectal surgery. Summary of Background Data: Machine learning (ML) has shown significant potential to advance medical fields, including surgical risk prediction. Current tools, like the ACS-RC which uses logistic regression and extreme gradient boosting, are standard but may be enhanced by more advanced ML ensembles. Methods: This retrospective study analyzed colorectal surgery cases from the 2018-2022 ACS National Surgical Quality Improvement Program (NSQIP) database. An SL model, which combines multiple ML algorithms, was developed to predict fourteen postoperative outcomes. Its performance was compared against traditional logistic regression (LOG) and extreme gradient boosting (XGB) models. Key performance metrics included discrimination (AUROC, AUPRC) and calibration (Brier score, Hosmer-Lemeshow test). Results: The SL model demonstrated superior performance across all predicted complications when compared to both LOG and XGB. It showed superior discrimination for severe outcomes, achieving an AUROC greater than 0.94 for predicting mortality. The SL model was also more accurate in predicting infectious complications and length of stay, and its calibration metrics indicated a better overall fit and accuracy. Conclusions: The Super Learner model enhances the accuracy of postoperative risk prediction in colorectal surgery. Its superior performance suggests it is a promising tool for improving personalized patient counseling, aiding clinical decision-making, and optimizing resource allocation.
Pediatric Admissions During the COVID-19 Pandemic in a Hospital with Low Prevalence of SARS-CoV-2
Mitzelfelt, Jordon C., Whelan, Jaclyn, Wieneke, Patrick, Authement, Matthew C. , Knoebel, Erin E., Kirkpatrick, T. Percy C. , Kawai, Yu , Mitzelfelt, Jordon C , Kawai, Yu , Mara, Kristin C. , Whelan, Jaclyn, Hall, David J. , Kirkpatrick, Travis R., Nemergut, Michael E.

Mayo Clinic

No container title available | July 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.175327205.54018587/v1 Get It

Background : The COVID-19 pandemic profoundly impacted healthcare, emphasizing the need to strengthen future pandemic responses and optimize resource allocation planning and deployment during times of disruption and crisis. Methods : This retrospective, single-center, cross-sectional study included participants ≤17 years-old admitted to the Children’s Hospital (CH) between 01/01/2017 and 12/31/2021. Clinical data was abstracted using Vizient ® Clinical Data Base and the internal data warehouse. Using the International Classification of Disease, 10 th Revision, Clinical Modification (ICD-10-CM) admit diagnosis, frequency and pattern of total admissions during the pre-pandemic phase (2017 Q1-2019 Q4) and intra-pandemic phase (2020 Q1-2021 Q4) were compared. Results : The study included 33,158 admissions. CH SARS-CoV-2 prevalence rate was 0.1% in 2020 and 0.5% in 2021. There was a decrease in overall admissions to the CH (p <0.01) and PICU (p <0.01) at the start of the pandemic. There were significant and variable differences in admission patterns for certain infectious, mental health, and seizure related diagnoses. Seasonality was noted for viral bronchiolitis during the pre-pandemic phase but was disrupted during the intra-pandemic phase with significantly lower admission rates for viral bronchiolitis in 2020 Q4 (p <0.05) and 2021 Q1 (p <0.01), followed by a significant early increase in viral bronchiolitis admissions in 2021 Q3 (p <0.01). Conclusion : The COVID-19 pandemic significantly impacted the number and pattern of admissions despite low SARS-CoV-2 prevalence in our hospital. These changes may be secondary to COVID-19 mitigation strategies implemented in the community. Results can inform anticipated patterns during future pandemics.
Redifferentiation Therapy for RAI-Refractory Thyroid Cancer
Greca, Amanda La , Boucai, Laura , Shonka, David C. , Chintakuntlawar, Ashish V.

Mayo Clinic

Clinical Thyroidology® | July 22, 2025 | Volume: 37 | Issue: 7 | Pages: 254-257

10.1089/ct.2025;37.254-257 Get It